ALCoFusion监测:ALK阳性肺癌ctDNA治疗反应与耐药分析
本研究评估了血浆循环肿瘤DNA(ctDNA)检测在ALK阳性非小细胞肺癌(NSCLC)患者中对恩沙替尼(ensartinib)治疗反应和耐药监测的效用。76例患者治疗前血浆中74%检出肿瘤相关基因变异,血浆与组织ALK融合一致性达91%;携带EML4-ALK V1融合患者对恩沙替尼的缓解率(53%)高于V3融合患者(14%),纵向监测可追踪耐药相关ALK变异变化。
要点
- 治疗前ctDNA可检出ALK融合,与组织一致性高达91%。
- EML4-ALK V1融合患者对恩沙替尼缓解率高于V3融合患者。
- 纵向ctDNA监测可追踪ALK变异变化以反映耐药。
核心结论
- ctDNA在治疗前可识别可能从恩沙替尼更多获益的ALK阳性NSCLC亚组,纵向监测可追踪耐药。
- 前瞻性应用该技术可能改善接受ALK酪氨酸激酶抑制剂治疗的NSCLC患者结局。
研究设计与样本
- 研究纳入76例ALK阳性NSCLC患者,采集治疗前血浆分析特定基因变异。
- 对其中11例患者进行纵向血浆样本分析。
- 比较22例患者治疗前肿瘤活检标本与血浆的检测结果。
主要发现
- 74%(56/76)患者血浆中检出疾病相关基因变异,最常见为EML4-ALK。
- 血浆与组织间ALK融合一致性为91%(20/22)。
- 15例患者中检出24个ALK激酶域突变,均曾接受ALK TKI治疗,G1269A最常见(4/24)。
- 携带EML4-ALK V1融合患者中9/17(53%)对恩沙替尼缓解,V3融合患者中1/7(14%)缓解。
- 治疗期间观察到ALK变异序列变化。
临床怎么用
- 可考虑治疗前采用ctDNA检测ALK融合及变异类型以辅助预测恩沙替尼疗效。
- 治疗过程中可纵向监测ctDNA中ALK变异变化以追踪耐药。
局限性
- 纵向分析样本量较小(n=11)。
- 研究未报告前瞻性验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of genetic alterations detected in circulating tumor DNA (ctDNA) can be an informative strategy to identify response and resistance. This study evaluated the utility of analyzing ctDNA as a function of response to ensartinib, a potent second-generation ALK TKI. METHODS: Pre-treatment plasma was collected from 76 patients with ALK+ NSCLC who were ALK TKI-naive or had received prior ALK TKI, and analyzed for specific genetic alterations. Longitudinal plasma samples were analyzed from a subset (n = 11) of patients. Analysis of pre-treatment tumor biopsy specimens from 22 patients was compared with plasma. RESULTS: Disease-associated genetic alterations were detected in 74% (56 of 76) of patients, the most common being EML4-ALK. Concordance of ALK fusion between plasma and tissue was 91% (20 of 22 blood and tissue samples). Twenty-four ALK kinase domain mutations were detected in 15 patients, all had previously received an ALK TKI; G1269A was the most prevalent (4 of 24). Patients with a detectable EML4-ALK variant 1 (V1) fusion had improved response (9 of 17 patients; 53%) to ensartinib compared to patients with EML4-ALK V3 fusion (one of seven patients; 14%). Serial changes in ALK alterations were observed during therapy. CONCLUSIONS: Clinical utility of ctDNA was shown, both at pre-treatment by identifying a potential subgroup of ALK+ NSCLC patients who may derive more benefit from ensartinib and longitudinally by tracking resistance. Prospective application of this technology may translate to improved outcomes for NSCLC patients treated with ALK TKIs.
引用
- Horn L, Whisenant JG, Wakelee H, et al. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol. 2019. PMID: 31446141. doi:10.1016/j.jtho.2019.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。